Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong
Background and Aim In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12–24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2017-06, Vol.32 (6), p.1230-1233 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1233 |
|---|---|
| container_issue | 6 |
| container_start_page | 1230 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 32 |
| creator | Chan, Henry Lik‐Yuen Tsang, Owen Tak‐Yin Hui, Yee‐Tak Fung, James Lui, Grace Chung‐Yan Lai, Ching‐Lung Wong, Grace Lai‐Hung Chan, Kam‐Hon But, David Yiu‐Kuen Lai, Moon‐Sing Lao, Wai‐Cheung Chan, Carmen Ka‐Man Lam, Yip‐Shun Seto, Wai‐Kay Li, Carlton Yuen, Man‐Fung Wong, Vincent Wai‐Sun |
| description | Background and Aim
In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12–24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong.
Methods
We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program.
Results
Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co‐infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty‐five (85%) patients received 12‐week treatment and six patients received 24‐week treatment; 26 (63%) patients received ribavirin combination. Thirty‐nine (95%; 95% confidence interval 88.5–100%) patients had undetectable HCV RNA at 12‐week post‐treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation.
Conclusions
Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real‐life clinical setting in Hong Kong. |
| doi_str_mv | 10.1111/jgh.13663 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1920490104</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1920490104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4193-fb0150a7a0e36cbfc3b2ce4562ab22db622a520b1fa6cd4224440f0d73eaf2603</originalsourceid><addsrcrecordid>eNp1kM1OGzEURi1ERVJgwQtUllhV6iTXP-PJLFEEpBSpEoL16NpjE0fJzNSegLIrb9Bn7JPUQ4BdvbA_28efpUPIGYMJS2O6elxOmFBKHJAxkxIyVkh1SMYwY3lWClaOyOcYVwAgociPyIgXM1UKPhuTlzuL67-__6y9s9Q65w2aHcWmphGd7Xe0dbTD4Hvsgn3yYZpi22BK32i70ek8vubhRY0R9TZtqW-oWYa28YYubYe9732kczok2_RxuF-0zSP9kaYT8snhOtrTt_WYPFxd3s8X2e3P6-_zi9vMSFaKzGlgOWCBYIUy2hmhubEyVxw157VWnGPOQTOHytSSc5lEOKgLYdFxBeKYnO97u9D-2trYV6t2G5r0ZcVKDrIEBjJRX_eUCW2MwbqqC36DYVcxqAbZVZJdvcpO7Je3xq3e2PqDfLebgOkeePZru_t_U3VzvdhX_gNMLosF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1920490104</pqid></control><display><type>article</type><title>Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chan, Henry Lik‐Yuen ; Tsang, Owen Tak‐Yin ; Hui, Yee‐Tak ; Fung, James ; Lui, Grace Chung‐Yan ; Lai, Ching‐Lung ; Wong, Grace Lai‐Hung ; Chan, Kam‐Hon ; But, David Yiu‐Kuen ; Lai, Moon‐Sing ; Lao, Wai‐Cheung ; Chan, Carmen Ka‐Man ; Lam, Yip‐Shun ; Seto, Wai‐Kay ; Li, Carlton ; Yuen, Man‐Fung ; Wong, Vincent Wai‐Sun</creator><creatorcontrib>Chan, Henry Lik‐Yuen ; Tsang, Owen Tak‐Yin ; Hui, Yee‐Tak ; Fung, James ; Lui, Grace Chung‐Yan ; Lai, Ching‐Lung ; Wong, Grace Lai‐Hung ; Chan, Kam‐Hon ; But, David Yiu‐Kuen ; Lai, Moon‐Sing ; Lao, Wai‐Cheung ; Chan, Carmen Ka‐Man ; Lam, Yip‐Shun ; Seto, Wai‐Kay ; Li, Carlton ; Yuen, Man‐Fung ; Wong, Vincent Wai‐Sun</creatorcontrib><description>Background and Aim
In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12–24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong.
Methods
We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program.
Results
Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co‐infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty‐five (85%) patients received 12‐week treatment and six patients received 24‐week treatment; 26 (63%) patients received ribavirin combination. Thirty‐nine (95%; 95% confidence interval 88.5–100%) patients had undetectable HCV RNA at 12‐week post‐treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation.
Conclusions
Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real‐life clinical setting in Hong Kong.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.13663</identifier><identifier>PMID: 27869328</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject><![CDATA[Anilides - administration & dosage ; Antiviral Agents - administration & dosage ; antiviral treatment ; Carbamates - administration & dosage ; Chronic infection ; Cirrhosis ; Coinfection ; Data processing ; Drug Administration Schedule ; Drug Therapy, Combination ; Genotype ; Genotype & phenotype ; Hepacivirus - genetics ; Hepatitis ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; HIV ; HIV Infections ; Hong Kong ; Hospitals ; Human immunodeficiency virus ; Infections ; Interferon ; Kidneys ; Liver Cirrhosis ; Liver Transplantation ; Macrocyclic Compounds - administration & dosage ; real‐life ; Renal failure ; Retrospective Studies ; Ribavirin ; Ribavirin - administration & dosage ; Ribonucleic acid ; Ritonavir ; Ritonavir - administration & dosage ; RNA ; Sulfonamides - administration & dosage ; Time Factors ; Transplantation ; Treatment Outcome ; Uracil - administration & dosage ; Uracil - analogs & derivatives]]></subject><ispartof>Journal of gastroenterology and hepatology, 2017-06, Vol.32 (6), p.1230-1233</ispartof><rights>2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><rights>2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><rights>2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4193-fb0150a7a0e36cbfc3b2ce4562ab22db622a520b1fa6cd4224440f0d73eaf2603</citedby><cites>FETCH-LOGICAL-c4193-fb0150a7a0e36cbfc3b2ce4562ab22db622a520b1fa6cd4224440f0d73eaf2603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.13663$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.13663$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27869328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chan, Henry Lik‐Yuen</creatorcontrib><creatorcontrib>Tsang, Owen Tak‐Yin</creatorcontrib><creatorcontrib>Hui, Yee‐Tak</creatorcontrib><creatorcontrib>Fung, James</creatorcontrib><creatorcontrib>Lui, Grace Chung‐Yan</creatorcontrib><creatorcontrib>Lai, Ching‐Lung</creatorcontrib><creatorcontrib>Wong, Grace Lai‐Hung</creatorcontrib><creatorcontrib>Chan, Kam‐Hon</creatorcontrib><creatorcontrib>But, David Yiu‐Kuen</creatorcontrib><creatorcontrib>Lai, Moon‐Sing</creatorcontrib><creatorcontrib>Lao, Wai‐Cheung</creatorcontrib><creatorcontrib>Chan, Carmen Ka‐Man</creatorcontrib><creatorcontrib>Lam, Yip‐Shun</creatorcontrib><creatorcontrib>Seto, Wai‐Kay</creatorcontrib><creatorcontrib>Li, Carlton</creatorcontrib><creatorcontrib>Yuen, Man‐Fung</creatorcontrib><creatorcontrib>Wong, Vincent Wai‐Sun</creatorcontrib><title>Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aim
In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12–24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong.
Methods
We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program.
Results
Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co‐infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty‐five (85%) patients received 12‐week treatment and six patients received 24‐week treatment; 26 (63%) patients received ribavirin combination. Thirty‐nine (95%; 95% confidence interval 88.5–100%) patients had undetectable HCV RNA at 12‐week post‐treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation.
Conclusions
Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real‐life clinical setting in Hong Kong.</description><subject>Anilides - administration & dosage</subject><subject>Antiviral Agents - administration & dosage</subject><subject>antiviral treatment</subject><subject>Carbamates - administration & dosage</subject><subject>Chronic infection</subject><subject>Cirrhosis</subject><subject>Coinfection</subject><subject>Data processing</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>HIV</subject><subject>HIV Infections</subject><subject>Hong Kong</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Infections</subject><subject>Interferon</subject><subject>Kidneys</subject><subject>Liver Cirrhosis</subject><subject>Liver Transplantation</subject><subject>Macrocyclic Compounds - administration & dosage</subject><subject>real‐life</subject><subject>Renal failure</subject><subject>Retrospective Studies</subject><subject>Ribavirin</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribonucleic acid</subject><subject>Ritonavir</subject><subject>Ritonavir - administration & dosage</subject><subject>RNA</subject><subject>Sulfonamides - administration & dosage</subject><subject>Time Factors</subject><subject>Transplantation</subject><subject>Treatment Outcome</subject><subject>Uracil - administration & dosage</subject><subject>Uracil - analogs & derivatives</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1OGzEURi1ERVJgwQtUllhV6iTXP-PJLFEEpBSpEoL16NpjE0fJzNSegLIrb9Bn7JPUQ4BdvbA_28efpUPIGYMJS2O6elxOmFBKHJAxkxIyVkh1SMYwY3lWClaOyOcYVwAgociPyIgXM1UKPhuTlzuL67-__6y9s9Q65w2aHcWmphGd7Xe0dbTD4Hvsgn3yYZpi22BK32i70ek8vubhRY0R9TZtqW-oWYa28YYubYe9732kczok2_RxuF-0zSP9kaYT8snhOtrTt_WYPFxd3s8X2e3P6-_zi9vMSFaKzGlgOWCBYIUy2hmhubEyVxw157VWnGPOQTOHytSSc5lEOKgLYdFxBeKYnO97u9D-2trYV6t2G5r0ZcVKDrIEBjJRX_eUCW2MwbqqC36DYVcxqAbZVZJdvcpO7Je3xq3e2PqDfLebgOkeePZru_t_U3VzvdhX_gNMLosF</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Chan, Henry Lik‐Yuen</creator><creator>Tsang, Owen Tak‐Yin</creator><creator>Hui, Yee‐Tak</creator><creator>Fung, James</creator><creator>Lui, Grace Chung‐Yan</creator><creator>Lai, Ching‐Lung</creator><creator>Wong, Grace Lai‐Hung</creator><creator>Chan, Kam‐Hon</creator><creator>But, David Yiu‐Kuen</creator><creator>Lai, Moon‐Sing</creator><creator>Lao, Wai‐Cheung</creator><creator>Chan, Carmen Ka‐Man</creator><creator>Lam, Yip‐Shun</creator><creator>Seto, Wai‐Kay</creator><creator>Li, Carlton</creator><creator>Yuen, Man‐Fung</creator><creator>Wong, Vincent Wai‐Sun</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201706</creationdate><title>Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong</title><author>Chan, Henry Lik‐Yuen ; Tsang, Owen Tak‐Yin ; Hui, Yee‐Tak ; Fung, James ; Lui, Grace Chung‐Yan ; Lai, Ching‐Lung ; Wong, Grace Lai‐Hung ; Chan, Kam‐Hon ; But, David Yiu‐Kuen ; Lai, Moon‐Sing ; Lao, Wai‐Cheung ; Chan, Carmen Ka‐Man ; Lam, Yip‐Shun ; Seto, Wai‐Kay ; Li, Carlton ; Yuen, Man‐Fung ; Wong, Vincent Wai‐Sun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4193-fb0150a7a0e36cbfc3b2ce4562ab22db622a520b1fa6cd4224440f0d73eaf2603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anilides - administration & dosage</topic><topic>Antiviral Agents - administration & dosage</topic><topic>antiviral treatment</topic><topic>Carbamates - administration & dosage</topic><topic>Chronic infection</topic><topic>Cirrhosis</topic><topic>Coinfection</topic><topic>Data processing</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>HIV</topic><topic>HIV Infections</topic><topic>Hong Kong</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Infections</topic><topic>Interferon</topic><topic>Kidneys</topic><topic>Liver Cirrhosis</topic><topic>Liver Transplantation</topic><topic>Macrocyclic Compounds - administration & dosage</topic><topic>real‐life</topic><topic>Renal failure</topic><topic>Retrospective Studies</topic><topic>Ribavirin</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribonucleic acid</topic><topic>Ritonavir</topic><topic>Ritonavir - administration & dosage</topic><topic>RNA</topic><topic>Sulfonamides - administration & dosage</topic><topic>Time Factors</topic><topic>Transplantation</topic><topic>Treatment Outcome</topic><topic>Uracil - administration & dosage</topic><topic>Uracil - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chan, Henry Lik‐Yuen</creatorcontrib><creatorcontrib>Tsang, Owen Tak‐Yin</creatorcontrib><creatorcontrib>Hui, Yee‐Tak</creatorcontrib><creatorcontrib>Fung, James</creatorcontrib><creatorcontrib>Lui, Grace Chung‐Yan</creatorcontrib><creatorcontrib>Lai, Ching‐Lung</creatorcontrib><creatorcontrib>Wong, Grace Lai‐Hung</creatorcontrib><creatorcontrib>Chan, Kam‐Hon</creatorcontrib><creatorcontrib>But, David Yiu‐Kuen</creatorcontrib><creatorcontrib>Lai, Moon‐Sing</creatorcontrib><creatorcontrib>Lao, Wai‐Cheung</creatorcontrib><creatorcontrib>Chan, Carmen Ka‐Man</creatorcontrib><creatorcontrib>Lam, Yip‐Shun</creatorcontrib><creatorcontrib>Seto, Wai‐Kay</creatorcontrib><creatorcontrib>Li, Carlton</creatorcontrib><creatorcontrib>Yuen, Man‐Fung</creatorcontrib><creatorcontrib>Wong, Vincent Wai‐Sun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chan, Henry Lik‐Yuen</au><au>Tsang, Owen Tak‐Yin</au><au>Hui, Yee‐Tak</au><au>Fung, James</au><au>Lui, Grace Chung‐Yan</au><au>Lai, Ching‐Lung</au><au>Wong, Grace Lai‐Hung</au><au>Chan, Kam‐Hon</au><au>But, David Yiu‐Kuen</au><au>Lai, Moon‐Sing</au><au>Lao, Wai‐Cheung</au><au>Chan, Carmen Ka‐Man</au><au>Lam, Yip‐Shun</au><au>Seto, Wai‐Kay</au><au>Li, Carlton</au><au>Yuen, Man‐Fung</au><au>Wong, Vincent Wai‐Sun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>32</volume><issue>6</issue><spage>1230</spage><epage>1233</epage><pages>1230-1233</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aim
In registration studies, combination therapy of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with and without ribavirin for 12–24 weeks can achieve > 90% sustained virological response (SVR) for genotype 1 hepatitis C virus (HCV) infection. However, data in Asia is scanty. We aimed to study the efficacy and safety of this combination therapy in chronic hepatitis C patients in Hong Kong.
Methods
We retrospectively analyzed data from six local hospitals that have prescribed PrOD with and without ribavirin to patients with genotype 1 chronic HCV infection as part of a global compassionate program.
Results
Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co‐infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation. Thirty‐five (85%) patients received 12‐week treatment and six patients received 24‐week treatment; 26 (63%) patients received ribavirin combination. Thirty‐nine (95%; 95% confidence interval 88.5–100%) patients had undetectable HCV RNA at 12‐week post‐treatment, that is, SVR. The two patients who did not develop SVR discontinued treatment prematurely; both of them were treatment experienced with liver cirrhosis complicated by acute renal failure unrelated to the treatment of PrOD and ribavirin. No patient had hepatic decompensation.
Conclusions
Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real‐life clinical setting in Hong Kong.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27869328</pmid><doi>10.1111/jgh.13663</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2017-06, Vol.32 (6), p.1230-1233 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_journals_1920490104 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anilides - administration & dosage Antiviral Agents - administration & dosage antiviral treatment Carbamates - administration & dosage Chronic infection Cirrhosis Coinfection Data processing Drug Administration Schedule Drug Therapy, Combination Genotype Genotype & phenotype Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology HIV HIV Infections Hong Kong Hospitals Human immunodeficiency virus Infections Interferon Kidneys Liver Cirrhosis Liver Transplantation Macrocyclic Compounds - administration & dosage real‐life Renal failure Retrospective Studies Ribavirin Ribavirin - administration & dosage Ribonucleic acid Ritonavir Ritonavir - administration & dosage RNA Sulfonamides - administration & dosage Time Factors Transplantation Treatment Outcome Uracil - administration & dosage Uracil - analogs & derivatives |
| title | Real‐life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A53%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90life%20efficacy%20and%20safety%20of%20paritaprevir/ritonavir,%20ombitasvir,%20and%20dasabuvir%20in%20chronic%20hepatitis%20C%20patients%20in%20Hong%20Kong&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Chan,%20Henry%20Lik%E2%80%90Yuen&rft.date=2017-06&rft.volume=32&rft.issue=6&rft.spage=1230&rft.epage=1233&rft.pages=1230-1233&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.13663&rft_dat=%3Cproquest_cross%3E1920490104%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1920490104&rft_id=info:pmid/27869328&rfr_iscdi=true |